IndraLab

Statements

USP8 binds CNOT11. 4 / 4
| 4
sparser
"In particular, C40-USP8 was used as a catalytically active mutant whereas the recently identified G664R USP8 mutant located in the autoinhibitory region was included in this study for further investigation [ xref , xref ]."
35626057
sparser
"However, cell transfection with S718del USP8 and C40-USP8 mutants in in vitro sensitive cultures from USP8 wild-type tumors abolished their ability to respond to pasireotide and did not confer pasireotide responsiveness to the in vitro resistant culture."
35626057
sparser
"Two of the four in vitro sensitive tumors (−17.1 ± 5.7% and −29.3 ± 1.1% secretion vs. basal for tumors #1 and #2, respectively, p < 0.05) were transiently transfected with S718del USP8 mutant while the remaining two in vitro sensitive tumors (−38.2 ± 2% and −22.7 ± 3.5% secretion vs. basal for tumors #4 and #5, respectively, p < 0.05) with the C40-USP8 mutant."
35626057
sparser
"Cell transfection with S718del USP8 and C40-USP8 mutants in responsive primary cultures bearing wild-type USP8 caused a complete loss of their ability to respond to the antisecretory action of pasireotide."
35626057